Sabinsa Corp. (East Windsor, NJ) now holds a U.S. patent for the company’s shelf-stable Bacillus coagulans MTCC 5856 probiotic ingredient, brand name LactoSpore, for therapeutic management of irritable bowel syndrome (IBS).
The patent (No. US9579352) relates to LactoSpore’s ability, concurrently with regular treatment, to help manage IBS symptoms such as abdominal pain, bloating or visible distension of the abdomen, constipation, and loose stools when the ingredient is administered orally as a dietary supplement in a dosage not less than 2 billion spores.
This ability was most recently backed by a published human study last year in Nutrition Journal that found that subjects taking 2 x 109 CFU/day of B. coagulans MTCC 5856 for 90 days saw decreases over the placebo group in symptoms such as bloating, vomiting, diarrhea, abdominal pain, and stool frequency.
In Canada, LactoSpore can be sold under the health claim, “Helps relieve abdominal pain associated with IBS.”
Majeed M et al., “Bacillus coagulans MTCC 5856 supplementation in the management of diarrhea predominant Irritable Bowel Syndrome: a double blind randomized placebo controlled pilot clinical study,” Nutrition Journal. Published online February 27, 2016.